Skip to main content
HYUNDAI PHARMACEUTICAL CO., LTD logo

HYUNDAI PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 004310 ISIN · KR7004310009 KO Manufacturing
Open in API
Filings indexed 183 across all filing types
Latest filing 2026-04-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 004310

About HYUNDAI PHARMACEUTICAL CO., LTD

http://www.hyundaipharm.co.kr/english

HYUNDAI PHARMACEUTICAL CO., LTD. is a company engaged in the research, development, manufacturing, and distribution of pharmaceutical products, medical devices, and health-focused food and beverages. The company's portfolio encompasses a broad range of prescription (ETC) and over-the-counter (OTC) medicines. Key therapeutic areas include dermatology, respiratory and gastrointestinal disorders, as well as treatments for conditions such as hypertension and dementia. With a strong commitment to innovation, the company focuses on the research of new substances and the continuous development of its drug pipeline. It also serves as a strategic partner for global companies, facilitating market entry and collaboration through its business development initiatives.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.02)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for Hyundai Pharm, covering the 1st quarter of the 63rd fiscal year (2025-12-01 to 2026-02-28). It contains detailed business information, financial data, production statistics, and R&D activities. As it is a comprehensive financial report for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report (IR). Q1 2026
2026-04-14 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 1% confidence The document is a Korean disclosure titled “투자판단 관련 주요경영사항” (“Material Information Related to Investment Decisions”) regarding the voluntary suspension of a Phase 3 clinical trial by Hyundai Pharm. It is not an annual or interim report, earnings release, or any financial statement, but rather a regulatory announcement of an operational event. This falls into the fallback category of general regulatory filings (RNS).
2026-03-26 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of shares by Shin Poong Pharm. Co., Ltd. in Hyundai Pharm. Co., Ltd. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) as it tracks changes in significant ownership levels that cross regulatory reporting thresholds.
2026-03-04 Korean
[기재정정]주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 1% confidence The document is a formal regulatory filing titled '주요사항보고서(자기주식 처분 결정)' which translates to 'Major Report (Decision on Disposal of Treasury Shares)'. It details the company's decision to sell its own shares (treasury stock) to specific entities for capital and strategic purposes. According to the provided definitions, the category 'Transaction in Own Shares' (POS) is specifically for reports of the company buying back or selling its own shares.
2026-02-27 Korean
타법인주식및출자증권취득결정
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory disclosure regarding the acquisition of shares in another company (Daehwa Pharmaceutical) by Hyundai Pharm. It details the acquisition amount, purpose, and board approval, which is a standard corporate announcement for M&A or strategic investment activity. Since it describes a specific transaction involving the acquisition of equity in another entity, it falls under the M&A Activity category.
2026-02-27 Korean
자기주식처분결과보고서
Transaction in Own Shares Classification · 1% confidence The document is a 'Report on the Results of Disposal of Treasury Shares' (자기주식처분결과보고서) filed by Hyundai Pharm Co., Ltd. to the Financial Supervisory Service. It details the specific number of shares sold, the disposal price, the counterparties involved, and the resulting change in treasury share holdings. This falls directly under the category of 'Transaction in Own Shares' (POS), which covers both buybacks and the disposal/sale of treasury shares.
2026-02-27 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.